Publicacións en colaboración con investigadores/as de Consiglio Nazionale delle Ricerche (19)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. N-Adamantyl-1-alkyl-4-oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as Fluorescent Probes to Detect Microglia Activation through the Imaging of Cannabinoid Receptor Subtype 2 (CB2R)

    Journal of Medicinal Chemistry

  3. Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip), Pisa, Italy, 28–29 September 2023

    Annales d'Endocrinologie

2023

  1. Antiviral Peptides Delivered by Chitosan-Based Nanoparticles to Neutralize SARS-CoV-2 and HCoV-OC43

    Pharmaceutics, Vol. 15, Núm. 6

  2. Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis

    Journal of Controlled Release, Vol. 360, pp. 747-758

  3. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  4. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  5. Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT6 receptor interaction

    Bioorganic and Medicinal Chemistry, Vol. 84

2022

  1. HuR-targeted agents: An insight into medicinal chemistry, biophysical, computational studies and pharmacological effects on cancer models

    Advanced Drug Delivery Reviews, Vol. 181

2021

  1. Pharmacological inactivation of the prion protein by targeting a folding intermediate

    Communications Biology, Vol. 4, Núm. 1

  2. Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases

    ChemMedChem, Vol. 16, Núm. 18, pp. 2807-2816

2020

  1. European lipodystrophy registry: Background and structure

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

2019

  1. Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning

    Experimental and Molecular Medicine, Vol. 51, Núm. 8

2018

  1. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  2. Laminopathies

    Nucleus (Austin, Tex.)

2010

  1. Reduced adipogenic gene expression in fibroblasts from a patient with type 2 congenital generalized lipodystrophy

    Diabetic Medicine, Vol. 27, Núm. 10, pp. 1178-1187

2009

  1. Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy

    Journal of Medical Genetics, Vol. 46, Núm. 1, pp. 40-48

2008

  1. 1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships

    Bioorganic and Medicinal Chemistry, Vol. 16, Núm. 22, pp. 9780-9789

  2. A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin resistance, aortic stenosis and hypertrophic cardiomyopathy

    Clinical Endocrinology, Vol. 69, Núm. 1, pp. 61-68